Catalent Stock Flat Following the Sell Agreement With Ardena
Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract Development and Manufacturing Organization with locations in Belgium,
Catalent to sell Somerset oral solids facility
Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement, which is expected to close in early 2025,
Catalent To Sell Oral Solids Development Facility In Somerset, NJ To Ardena
Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset,
Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey
Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday. Catalent provides contract manufacturing services and performs fill-finish work,
bovnews1d
Stock Shock: The Unpredictable Rise and Fall of CTLT—What’s Driving the Drama?
On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...
Catalent, Inc. (NYSE:CTLT) Receives $59.83 Average Target Price from Analysts
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...
Nasdaq1mon
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Investors might want to bet on Catalent (CTLT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
bovnews5d
Catalent Inc (CTLT) Stock: More Strategic Than Meets the Eye
On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.71 which represents a decrease of $-0.25 or -0.41% from the prior close of $60.96. The stock opened at $60.78 and touched a ...
Yahoo Finance9d
Catalent, Inc. (CTLT)
SOMERSET, N.J., August 29, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for ...
Sen. Elizabeth Warren wants FTC to scrutinize Novo Nordisk deal for Catalent
Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's ...